Since IRF8 is not among the canonical transcriptional targets of KMT2A fusion oncoproteins (Milne et al. 2002, 2005; Krivtsov et al. 2006, 2008, 2017; Krivtsov and Armstrong 2007; Guenther et al. 2008; Bernt et al. 2011; Kerry et al. 2017), we explored how IRF8 expression may be activated in KMT2A-rearranged AML. The gene discussed is IRF8; the disease is acute myeloid leukemia.